Volpara Health announces that it has received U.S. FDA clearance for the latest version of Volpara Imaging Software (VIS 3.2), which incorporates artificial intelligence learnings in Volpara’s breast density assessment algorithm. The clearance also expands the use of VIS 3.2 to additional mammography machines, increasing support for various Giotto and Siemens units, thus extending Volpara’s reach and multi-vendor capabilities.
Since receiving initial FDA clearance for Volpara Imaging Software in 2010, Volpara has now received four additional clearances for the key science algorithm behind its integrated Volpara Breast Health Platform—a product suite designed to enable earlier detection of breast cancers through improved mammography quality and workflow, volumetric assessment of breast density, and personalized breast care. Volpara’s technology is protected by 98 patents worldwide and is validated by more than 375 peer-reviewed publications and research abstracts.
The latest clearance includes Volpara’s Open Virtual Appliance architecture, which increases image processing security and makes it easier for Volpara to monitor, service, and update software services—a key part of the company’s strategic move to lay the foundations for future new products.
“These new innovations improve the overall security, scalability, robustness, and breadth of our breast health offering. Our objective with each enhancement is the pursuit of our mission—to eliminate advanced-stage breast cancer and save more families from cancer,” says Ralph Highnam, PhD, Volpara’s group CEO.